MTOR and renal cell carcinoma: Recently, however, therapies that target signaling pathways, such as immune checkpoint, tyrosine kinase (TKI), and mammalian target of rapamycin (mTOR) inhibitors, have steadily improved clinical results for advanced RCC [4,5].